Molecular basis for the Kallmann syndrome-linked fibroblast growth factor receptor mutation

Biochemical and Biophysical Research Communications

Volumn 425, Issue 3, 2012, Pages 673-678

  Thurman, Ryan D ^a   Kathir, Karuppanan Muthusamy ^a,b   Rajalingam, Dakshinamurthy ^a,c   Kumar, Thallapuranam K Suresh ^a  

^a UNIVERSITY OF ARKANSAS   (United States)

^b REGENERON PHARMACEUTICALS INC   (United States)

^c WESTERN KENTUCKY UNIVERSITY   (United States)

Author keywords

Fibroblast growth factor; Fibroblast growth factor receptor; Kallmann's syndrome; Nuclear magnetic resonance spectroscopy

Indexed keywords

FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR; HEPARIN;

ARTICLE; CONFORMATIONAL TRANSITION; FIBROBLAST GROWTH FACTOR RECEPTOR GENE; GENE; GENE MUTATION; KALLMANN SYNDROME; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROTEIN BINDING;

AMINO ACID SEQUENCE; FIBROBLAST GROWTH FACTOR 1; HEPARIN; HUMANS; KALLMANN SYNDROME; LIGANDS; MOLECULAR SEQUENCE DATA; MUTATION; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PROTEIN BINDING; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, FIBROBLAST GROWTH FACTOR;

EID: 84865537839     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.07.104     Document Type: Article

References (24)

1. Naftolin F., Harris G., Bobrow M. Effect of purified luteinizing hormone releasing factor on normal and hypogonadotrophic anosmic men. Nature 1971, 232:496-497.
2. Cadman S.M., Kim S.H., Hu Y., Gonzalez-Martinez D., Bouloux P.M. Molecular pathogenesis of kallmann's syndrome. Horm. Res. 2007, 67:231-242.
3. Albuisson J., Pecheux C., Carel J.C., Lacombe D., Leheup B., Lapuzina P., Legius E., Matthijs G., Wasniewska M., Dwlpech M., Young J., Hardelin J.P., Dode C. Kallmann syndrome: 14 novel mutations in KAL1 and FGFR1 (KAL2). Hum. Mutat. 2005, 25:98-99.
4. Gill J.C., Moenter S.M., Tsai P.S. Developmental regulation of gonadotropin-releasing hormone neurons by fibroblast growth factor signaling. Endocrinology 2004, 145:3830-3839.
5. Raivio T., Sidis Y., Plummer L., Chen H., Ma J., Mukherjee A., Jacobson-Dickman E., Quinton R., Van Vliet G., Lavoie H., Hughes V.A., Dwyer A., Hayes F.J., Xu S., Sparks S., Kaiser U.B., Mohammadi M., Pitteloud N. Impaired fibroblast growth factor receptor 1 signaling as a cause of normosmic idiopathic hypogonadotropic hypogonadism. J. Clin. Endocrinol. Metab. 2009, 94:4380-4390.
6. Pitteloud N., Acierno J.S., Meysing A.U., Dwyer A.A., Hayes F.J., Crowley W.F. Reversible kallmann syndrome, delayed puberty, and isolated anosmia occurring in a single family with a mutation in the fibroblast growth factor receptor 1 gene. J. Clin. Endocrinol. Metab. 2005, 90:1317-1322.
7. Colvin J., White A., Pratt S., Ornitz D. Lung hypoplasia and neonatal death in Fgf9-null mice identify this gene as an essential regulator of lung mesenchyme. Development 2001, 128:2095-2106.
8. Kathir K.M., Kumar T.K., Yu C. Understanding the mechanism of the antimitogenic activity of suramin. Biochemistry 2006, 45:899-906.
9. Plotnikov A.N., Hubbard S.R., Schlessinger J., Mohammadi M. Crystal structure of FGF2 in complex with the extracellular lignad binding domain of FGF receptor 2. Cell 2000, 101:413-424.
10. Hu Y., Guimond S.E., Travers P., Cadman S., Hohenester E., Turnbull J.E., Kim S.H., Bouloux P.M. Novel mechanisms of fibroblast growth factor receptor 1 regulation by extracellular matrix protein anosmin-1. J. Biol. Chem. 2009, 284:29905-29920.
11. Hu Y., Bouloux P.M. Novel insights in FGFR1 regulation: Lessons from kallmann syndrome. Trends Endocrinol. Metab. 2010, 21:385-393.
12. Pedersen-White J.R., Chorich L.P., Bick D.P., Sherins R.J., Layman L.C. The prevalence of intragenic deletions in patients with idiopathic hypogonadotropic hypogonadism and kallmann syndrome. Mol. Hum. Reprod. 2008, 14:367-370.
13. Pitteloud N., Quinton R., Pearce S., Raivio T., Acerno J., Dwyer A., Plummer L., Hughes V., Seminara S., Cheng Y., Li W., Maccoll G., Eliseenkova A.V., Olsen S.K., Ibrahimi O., Hayes F.J., Boepple P., Hall J.E., Bouloux P., Mohammadi M., Crowley W.J. Digenic mutations account for variable phenotypes in idiopathic hypogonadotropic hypogonadism. J. Clin. Invest. 2007, 117:457-463.
14. Sato N., Hasegawa T., Hori N., Fukami M., Yoshimura Y., Ogata T. Gonadotrophin therapy in kallmann syndrome caused by heterozygous mutations of the gene for fibroblast growth factor receptor 1: report of three families: case report. Hum. Reprod. 2005, 20:2173-2178.
15. Mitchell A.L., Dwyer A., Pitteloud N., Quinton R. Genetic basis and variable phenotypic expression of Kallmann syndrome: towards a unifying theory. Trends Endocrinol. Metab. 2011, 22:249-258.
16. Plotnikov A.N., Schlessinger J., Hubbard S.R., Mohammadi M. Structural basis for FGF receptor dimerization and activation. Cell 1999, 98:641-650.
17. Hebert J.M., Lin M., Partanen J., Rossant J., McConnell S.K. FGF signaling through FGFR1 is required for olfactory bulb morphogenesis. Development 2003, 130:1101-1111.
18. Hung K.W., Kumar T.K., Kathir K.M., Xu P., Ni F., Ji H.H., Chen M.C., Yang C.C., Lin F.P., Chiu I.M., Yu C. Solution structure of the ligand binding domain of the fibroblast growth factor receptor: role of heparin in the activation of the receptor. Biochemistry 2005, 44:15787-15798.
19. Plotnikov A.N., Hubbard S.R., Schlessinger J., Mohammadi M. Crystal structures of two FGF-FGFR complexes reveal the determinants of ligand-receptor specificity. Cell 2000, 101:413-424.
20. Kathir K.M., Kumar T.K., Rajalingam D., Yu C. Time-dependent changes in the denatured state(s) influence the folding mechanism of an all beta-sheet protein. J. Biol. Chem. 2005, 280:29682-29688.
21. Lepock J.R. Measurement of protein stability and protein denaturation in cells using differential scanning calorimetry. Methods 2005, 35:117-125.
22. Fontana A., de Laureto P.P., Spolaore B., Frare E., Picotti P., Zambonin M. Probing protein structure by limited proteolysis. Acta Biochim. Pol. 2004, 51:299-321.
23. Fontana A., Polverino de Laureto P., De Filippis V., Scaramella E., Zambonin M. Probing the partly folded states of proteins by limited proteolysis. Fold. Des. 1997, 2:R17-R26.
24. Yeh B.K., Eliseenkova A.V., Plotnikov A.N., Green D., Pinnell J., Polat T., Gritli-Linde A., Linhardt R.J., Mohammadi M. Structural basis for activation of fibroblast growth factor signaling by sucrose octasulfate. Mol. Cell. Biol. 2002, 22:7184-7192.